TITLE

A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

AUTHOR(S)
Ruperto, Nicolino; Eichler, Irmgard; Herold, Ralf; Vassal, Gilles; Giaquinto, Carlo; Hjorth, Lars; Valls-i-Soler, Adolf; Peters, Christina; Helms, Peter J.; Raymond, Agnès Saint
PUB. DATE
March 2012
SOURCE
Archives of Disease in Childhood;Mar2012, Vol. 97 Issue 3, p185
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses several national and international paediatric networks that are performing clinical trials in the paediatric population in Europe. It examines the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), an organization establish to investigate drug trials in Europe's paediatric population. The authors relate that performing drug trials are difficult due to various reasons including logical, methodological and ethnical problems.
ACCESSION #
71738465

 

Related Articles

  • Can ‘phase IV’ work for you? Borfitz, Deborah // Medical Economics;6/6/2003, Vol. 80 Issue 11, p58 

    Focuses on the controversies behind phase IV clinical trials in the U.S. Emphasis on creating a potentiated drug combinations; Collaboration between doctors and pharmaceutical companies to increase drug sales; Quality of drug studies conducted.

  • N.O.'s research facilities prove big draw for clinical drug trials. Kamerick, Megan // New Orleans CityBusiness (1994 to 2008);10/20/2003, Vol. 24 Issue 17, p35 

    Reports on the prevalence of clinical drug trials in New Orleans, Louisiana. Number of trials taking place at the Louisiana State University Health Sciences Center; Impact of the prevalence of clinical trials on the economy of the city; Credibility of academic health science in conducting the...

  • Clinical trials of medicines in children. Choonara, Imti // BMJ: British Medical Journal (International Edition);11/04/2000, Vol. 321 Issue 7269, p1093 

    Editorial. Focuses on the lack of scientific data related to the use of medicines in children. Reluctance of the pharmaceutical industry to conduct clinical trials of medicines in children; Efforts of the United States Food and Drug Administration (FDA) to encourage such studies; Practical...

  • Global clinical trial laboratories decentralize. Rosenberg, Ronald // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1 

    The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting...

  • The Quality of Registration of Clinical Trials. Viergever, Roderik F.; Ghersi, Davina // PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1 

    Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous...

  • News in brief . . .  // Reactions Weekly;6/18/2005, Issue 1056, p2 

    Presents updates on issues and events concerning medical researches in the U.S. as of June 2005. Reason for the temporary suspension of the clinical trial for the AV 1101 drug; Recommendations of Bristol-Myers Squibb for pregnant women taking the Sustiva drug; Postponement of the patient...

  • Trial results: the next battle. Abbasi, Kamran // BMJ: British Medical Journal (International Edition);1/15/2005, Vol. 330 Issue 7483, precedes p. 103 p103 

    Presents comments on an announcement by drug companies that results of clinical trials for drugs may soon become available to the public. Concerns about prescription drugs and their possible harmful effects; Assertion that unless the proposal to release clinical trial results is mandatory it...

  • For comparison's sake. Sloane, Todd // Modern Healthcare;11/27/2006, Vol. 36 Issue 47, p20 

    The author reflects on angioplasty studies. He claims that there is a problem of rarity in clinical trials involving the benefits of angioplasty and the use of stents. He thinks that drug companies and device makers that typically fund clinical research do not want to see independent reports...

  • CNS. Lazarus, Kim // Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p51 

    The article presents information on clinical trials that were conducted to test the efficacy of drugs including Almorexant Actilion. A study in patients with primary insomnia indicated that Almorexant significantly improved the primary parameter of sleep efficiency. In another trial it was found...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics